#Vaccines Market

[the-latest-research]

Vaccines Market Estimated to be Worth $71.50 Billion in 2031

Meticulous Research®– a leading global market research company, published a research report titled ‘Vaccines Market Size, Share, Forecast, & Trends Analysis by Indication (Pneumococcal, Influenza, HPV, DTP, MMR, Hepatitis, COVID-19) Administration (IM, SC, Oral) Type (Inactivated, Combination) Valence (Multivalent, Monovalent) - Global Forecast to 2031.’

According to this latest publication from Meticulous Research®, the vaccines market is projected to reach $71.50 billion by 2031, at a CAGR of 2.3% during the forecast period. This market's growth is driven by a strong pipeline for vaccines, increasing government initiatives toward immunization, and technological advancements in the vaccine industry. Moreover, the rising prevalence of diseases, growing focus on therapeutic vaccines, and growth prospects in emerging markets are expected to offer growth opportunities for the players operating in this market.

However, the high costs involved in vaccine development and the long timelines of vaccine manufacturing restrain the market’s growth. Additionally, product recalls and inadequate access to vaccines pose challenges to the market’s growth.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5076

Key Players

The key players operating in the vaccines market are Sanofi (France), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Johnson & Johnson (U.S.), Daiichi Sankyo Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), and AstraZeneca PLC (U.K.).

Vaccines Market: Future Outlook

The vaccines market is segmented based on Indication (Pneumococcal Disease, Influenza, Human Papillomavirus (HPV), Diphtheria, Tetanus, and Pertussis (DTP), Meningococcal Disease, Measles, Mumps, and Rubella (MMR), Rotavirus, Poliomyelitis (Polio), Hepatitis, COVID-19, Other Indications), Route of Administration (Intramuscular, Subcutaneous, Oral, Other Route of Administration), Type (Subunit & Conjugate Vaccines, Inactivated Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, Combination Vaccines), and Valence (Multivalent and Monovalent Vaccines) and Geography. The study also evaluates industry competitors and analyzes their market share at global and regional levels.

Based on indication, the vaccines market is segmented into pneumococcal disease, influenza, human papillomavirus (HPV), diphtheria, tetanus, pertussis (DTP), meningococcal disease, measles, mumps, rubella (MMR), rotavirus, poliomyelitis (polio), hepatitis, COVID-19, and other indications. In 2024, the pneumococcal disease segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the rising incidence of pneumococcal diseases such as pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis; and the development of quality vaccines such as PPSV23.

Based on route of administration, the vaccines market is segmented into intramuscular (IM), subcutaneous (SC), oral, and other routes of administration. In 2024, the intramuscular (IM) segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the ease of intramuscular administration and quick absorption of vaccines administered through the intramuscular route. Further, due to the COVID-19 pandemic, there has been increased adoption of the intramuscular route of administration, as many COVID-19 vaccines are being administered through this route.

Based on type, the vaccines market is segmented into subunit & conjugate vaccines, inactivated vaccines, live-attenuated vaccines, toxoid vaccines, and combination vaccines. In 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of the vaccines market. The large market share of this segment can be attributed to the subunit & conjugate vaccines’ long-term immunity, high safety, and stability compared to vaccines with other antigens.

Based on valence, the vaccines market is segmented into multivalent vaccines and monovalent vaccines. In 2024, the multivalent vaccines segment is expected to account for the larger share of the vaccines market. The large market share of this segment can be attributed to the launch of newer multivalent vaccines, increasing investments by key players in the R&D of multivalent vaccines, and technological advancements in the production of multivalent vaccines.

Geographic Review

This research report analyzes major geographies and provides comprehensive analysis for North America (U.S and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America) and Middle East & Africa. In 2024, North America is estimated to account for the largest share of 41.2% of the vaccines market, followed by Europe and Asia-Pacific. North America’s major market share is attributed to the growing research & development, product launches, and the establishment of new facilities in the region by key players.

Complete Report Here : https://www.meticulousresearch.com/product/vaccines-market-5076

Key Questions Answered in the Report:

Which high-growth market segments are in terms of indication, route of administration, type, valence, and regions/countries?

What was the historical market for vaccines across the globe?

What are the market forecasts and estimates for the period 2024-2031?

What are the major drivers, restraints, challenges, and opportunities in the vaccines market?

What is the competitive landscape like, and who are the market leaders in the vaccines market?

What are the recent developments in the vaccines market?

What strategies are adopted by the major players in the vaccines market?

What are the geographical trends and high-growth regions/countries?

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[techninja]

Navigating the Competitive Landscape of the Vaccines Market

Vaccine market growth

Vaccines play a pivotal role in safeguarding public health by preventing the spread of infectious diseases. As the need for vaccination continues to rise, the vaccine market has witnessed significant growth over the years. This article delves into the competitive landscape of the vaccines market, exploring its size, trends, analysis, research, and segmentation, while also highlighting the key industry trends shaping its future.

Vaccine market size

The vaccine market has experienced substantial expansion in recent times, thanks to increasing awareness, technological advancements, and government initiatives worldwide. According to market research reports, the global vaccine market was valued at over $50 billion in 2020 and is projected to witness a compound annual growth rate of more than 10% in the coming years. This remarkable growth can be attributed to several factors, including rising prevalence of infectious diseases, expanding immunization programs, and a surge in research and development activities.

Vaccine market trends

Keeping abreast of the latest vaccine market trends is crucial for industry professionals and stakeholders. One of the prominent trends in the vaccines market is the increasing focus on developing vaccines for emerging infectious diseases. With the recent outbreak of COVID-19, the demand for vaccines targeting novel pathogens has surged significantly. Additionally, there is a growing shift towards personalized vaccines, with the aim of improving efficacy and safety profiles. Furthermore, the adoption of innovative delivery methods, such as nasal sprays and microneedle patches, is gaining traction in the market.

Vaccines market analysis

In-depth analysis of the vaccines market helps industry players gain insights and make informed decisions. Market analysis involves examining various factors, such as market drivers, restraints, opportunities, and challenges. It also includes a comprehensive evaluation of competitive landscape, key players, market share, and strategic collaborations. Furthermore, analyzing regional dynamics and regulatory frameworks is crucial to understanding the market landscape on a global scale.

Vaccine market research

Rigorous and continuous research is the backbone of the vaccine industry. Extensive research efforts are dedicated to developing new vaccines, improving existing ones, and enhancing manufacturing processes. Research institutions, academic organizations, pharmaceutical companies, and governmental bodies contribute significantly to vaccine market research. Cutting-edge technologies, including genomics, proteomics, and bioinformatics, are revolutionizing the way vaccines are developed and tested. Continuous research and development activities are essential to meet the evolving healthcare needs of the global population.

Vaccine industry trends

Apart from the specific trends mentioned earlier, several overarching vaccine industry trends shape the future landscape. Vaccination campaigns are increasingly leveraging digital technologies for patient tracking, supply chain management, and adverse event reporting. Additionally, there is growing emphasis on vaccine supply and distribution logistics to ensure equitable access across different regions and populations. The vaccine industry is also witnessing collaborations between public and private sectors, fostering innovation, capacity building, and knowledge sharing.

Vaccine market segmentation

The vaccines market can be segmented based on various parameters, including disease type, technology, age group, and region. Disease-wise segmentation encompasses vaccines for infectious diseases, non-infectious diseases, and therapeutic vaccines. Technological segmentation encompasses traditional vaccines, recombinant vaccines, conjugate vaccines, and nucleic acid-based vaccines. Age group segmentation includes vaccines for pediatrics, adults, and geriatrics. Geographically, the vaccines market can be classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Analyzing these segments helps identify specific market dynamics and opportunities.

Global vaccines market

The global vaccines market is witnessing rapid expansion, driven by increasing investment in research and development, rising disease burden, and a proactive approach towards preventive healthcare. North America and Europe continue to dominate the market, owing to well-established healthcare infrastructure and favorable government policies. However, the Asia Pacific region is expected to witness robust growth due to the growing population, rising healthcare expenditure, and increasing awareness about vaccination. Major players in the global vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, and Merck & Co., Inc.

[soumyafwr]

https://uchatoo.com/read-blog/6773_vaccines-market-share-overview-competitive-analysis-and-forecast-2031.html

Vaccines Market Share, Overview, Competitive Analysis and Forecast 2031

[sighphi]

Another factor boosting market growth is the expansion of vaccination and immunization campaigns run by governments and public health groups....

[root-analysis]

mRNA Therapeutics & Vaccines Market | Trends and Forecast (2035)

The global mRNA therapeutics market is estimated to be worth over USD 51 billion in 2022; non-COVID-19 indications will drive the market growth during the forecast period 2023-2035. The Roots Analysis report features an extensive study of the current market overview of the mRNA therapeutics vaccines market over the forecast period. Get a detailed insights report now!

[dreaminginthedeepsouth]

deAdder

* * * *

Jim Wright

Trump has nominated Robert F. Kennedy Jr., a conspiracy nut and rabid anti-vaxxer, to lead the Department of Health and Human Services.

RFK Jr has a long, long history of insane, counterfactual, completely wrong, and at best misleading claims regarding vaccines. I don't thinks he's every said a single word about vaccines that was correct. There isn't an unhinged vaccine conspiracy theory Kennedy doesn't love and believe whole hog.

He's lost literally hundreds of lawsuits over vaccines.

But NOW he's going be in charge of vaccination for the entire country.

We're literally going to put the biggest nut in the booby hatch in charge, and we're going to lock up all the doctors.

Guess Liberals should have shown up, eh? Then again, anti-vax conspiracy theories have long been a popular bugaboo on the far left, which is where Kennedy himself came from, so maybe the Left is getting exactly what it wanted after all.

Be that as it may, or may not be, Kennedy has said the government won't out and out outlaw vaccines, but will just make it so they aren't mandated.

Vaccines won't be mandatory and no one from schools to employers to the military will be able to make them so.

(You probably don't want to spend too much time imagining the massive vulnerability any unvaccinated military will face in a battlespace where disposable $100 drones can easily spray biological agents over wide areas...)

Anyway, you'll still be able to get your family vaccinated.

But your insurance won't cover it.

Oh, you didn't think about THAT, did you?

Yeah, if vaccines aren't mandatory, AND the government agency tasked with certifying their effectiveness is run by a bunch of drooling lunatics who think Froot Loops make kids gay or something, well, then there isn't any way in hell that your insurance company is going to pay for them. Especially when they repeal the ACA slash Obamacare.

In practical terms what this means is that ONLY the rich will be fully vaccinated.

And the poor will be ravaged by disease.

Oh, and it's not just going to be measles, mumps, polio, whooping cough, flu, COVID, etc. No no. It'll be the classics like cholera and typhus too, because Trump, RFK, and the new Department of Government Efficiency run by Vivek Ramaswamy and Elon Musk, are ALSO going to get rid of health inspectors, you know, the people who make sure your food isn't contaminated by rat flees or your drinking water doesn't have human shit in it.

Don't worry, I'm sure the Free Market will sort it out soon enough, and at a profit too.

When Trump said make America like the 1700s again, Buddy, he wasn't kidding

[bisexualalienss]

get all your vaccines updated now. that’s all all going to say. including your covid vaccines

[nerdgirlnarrates]

Of the many things to be scared about, I am particularly fearful of what RFK Jr having a prominent role in public health would mean

[healthcareporium]

Immunomodulators' Power: Widening Applications and Medical Impact

Immunomodulators have emerged as crucial components in the field of medicine, gaining increasing attention for their ability to regulate and modify the immune system’s responses. These agents play a pivotal role in treating a diverse range of conditions, from autoimmune diseases and cancer to infectious diseases and organ transplants. By modulating immune responses, immunomodulators offer…

[soumyafwr]

https://www.cienciared.es/blogs/224562/Vaccines-Market-Share-Overview-Competitive-Analysis-and-Forecast-2031

Vaccines Market Share, Overview, Competitive Analysis and Forecast 2031

[spermarket]

United States Vaccine Market Demand, Trends, Revenue, Challenges, Future Investment and Growth Opportunities: SPER Market Research

The term “Vaccine” refers to a biological preparation intended to provide immunity against a specific infectious disease. It comprises infections that have been weakened or rendered inactive, or parts of the pathogen, including proteins or genetic material, that trigger the immune system to identify and combat the pathogen should it be encountered again. Vaccines provide long-term protection against the disease by encouraging the body to produce antibodies and memory cells that "remember" how to combat the virus. Vaccines have been essential in the management and elimination of many infectious illnesses, including measles, polio, and smallpox. Although they are usually provided by injection, they can also be taken orally or through the nose. One of the most successful public health strategies for lowering death and morbidity has been widespread immunisation. 

According to SPER Market Research, ‘United States Vaccine Market Size- By Product, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ states that the United States Vaccine Market is estimated to reach USD 30.54 billion by 2033 with a CAGR of 7.5%. 

Drivers: 

The need for vaccines in US has increased due to the rising incidence of infectious diseases, both imported and domestic. mRNA platforms are one example of how vaccine technology advancements have sped up development schedules and increased vaccine alternatives. Research and development of vaccines is supported by government programs and funds, such as the Biomedical Advanced Research and Development Authority (BARDA). Campaigns to raise public awareness have increased vaccination rates, which has helped to create herd immunity. Furthermore, the need for vaccines is growing as the ageing population becomes more vulnerable to illness. New infections have also been brought about by the growth of international travel and trade, making the creation of vaccines necessary to stop possible epidemics.  

Restraints: 

The US vaccine market still confronts a number of obstacles in spite of its expansion. Lower vaccination rates present dangers to public health because of vaccine reluctance and disinformation. The availability and affordability of vaccinations may be restricted by high production costs and intricate manufacturing procedures. Long approval procedures and regulatory obstacles may cause novel vaccinations to be introduced later than planned. Shortages and distribution issues can result from supply chain disruptions, as was the case during the COVID-19 epidemic. Inequalities in vaccination distribution continue to impact marginalised communities, raising concerns about equitable access to these treatments. Furthermore, the development of vaccines may not keep up with the introduction of new disease types, requiring quick adaption and licensing of novel formulations.  

Request a Free Sample Report: https://www.sperresearch.com/report-store/united-states-vaccine-market.aspx?sample=1

The COVID-19 pandemic had a major impact on the US vaccination market. Numerous COVID-19 vaccines were developed and approved quickly as a result of the extraordinary cooperation between government organisations, pharmaceutical corporations, and research institutes brought about by the urgent demand for vaccines. In order to restrict the virus's spread and establish herd immunity, mass vaccination operations were started. The pandemic made clear how crucial it is to have a strong infrastructure for vaccines and to be ready for any future public health emergency. But there were drawbacks to the quick implementation as well, such as logistical issues with distribution, public reluctance, and the requirement for ongoing evaluation of the vaccine's effectiveness against new variations. Following the pandemic, efforts to improve vaccine infrastructure have regained momentum.  

United States Vaccine Market is dominated by Boston due to biotech and pharmaceutical hub, access to venture capital and world class research institutions. Some of its key players are - AstraZeneca plc, Bharat Biotech, Berna Biotech Ltd., BIO-MED, Bilthoven Biologicals. 

For More Information, refer to below link: –  

United States Vaccine Market Growth

Related Reports:  

Platelet Rich Plasma Market Size- By Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Cold Pain Therapy Market Growth, Size, Trends Analysis - By Product, By Application, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

enquiries@sperresearch.com 

+1–347–460–2899

[root-analysis]

mRNA Therapeutics Vaccines Market Report | Forecast Period (2035)

In 2022, the worldwide market for mRNA therapeutics is valued at more than $51 billion. The Roots Analysis report thoroughly examines the present market situation and the future prospects of mRNA therapeutic vaccines market report. The market is anticipated to witness consistent market growth during the forecast period. Obtain a comprehensive insights report on this now!

[marketsndata]

India Human Papillomavirus Vaccine Market Size, Growth and Report 2032

India human papillomavirus vaccine market is projected to witness a CAGR of 11% during the forecast period FY2024-FY2031, growing from USD 1.3 billion in FY2023 to USD 3 billion in FY2031. Several factors are contributing to the growing market size, including a rise in awareness about the importance of HPV vaccination due to the increasing prevalence of cervical cancer and other diseases associated with HPV. In addition, various government-led initiatives and vaccination programs, as well as advancements in vaccine development technology, have played a crucial role in increasing awareness about vaccination.

In recent years, India human papillomavirus vaccine market has experienced substantial growth, driven by an increasing recognition of the significance of preventing HPV infections and their associated diseases. Cervical cancer, a leading cause of concern for millions of women in India, is primarily linked to HPV, a common sexually transmitted infection. The increasing awareness about the benefits of HPV vaccination and its potential to reduce the burden of cervical cancer has resulted in a surge in demand for HPV vaccines in India. In response, the Indian government and various healthcare organizations have undertaken numerous initiatives and vaccination programs to promote widespread vaccine adoption, with a particular focus on young girls and women.

Furthermore, advancements in vaccine development technology have paved the way for the introduction of more effective and accessible vaccines in India human papillomavirus vaccine market. These breakthroughs have instilled confidence among healthcare providers and individuals regarding the efficacy and safety of HPV vaccination. The rising popularity of HPV vaccines in India signals a promising step forward in the effort to combat HPV infections and safeguard the well-being of women across the country, positively impacting the India human papillomavirus vaccine market.

In December 2023, the Family Planning Association of India (FPAI) initiated a nationwide HPV vaccination drive for girls and women to protect them against cervical cancer. The campaign’s objective is to vaccinate over 20,000 women and girls through the FPAI’s 40 branches spread across the country.

Increasing Awareness About HPV Immunization

Increasing awareness about the importance of HPV vaccination has led to significant growth of India human papillomavirus vaccine market. While efforts implemented by governments and healthcare organizations have increased screening for cervical cancer, the primary prevention achieved through HPV immunization has played a crucial role in diminishing the cervical cancer burden in India. The effectiveness of these strategies has been evident not only in high-income countries (HICs) but has also resulted in higher rates of adoption of the HPV vaccine and widespread approval in low- and lower-middle-income countries (LLMICs). International collaborations between WHO, United Nations Population Fund, UN Women, and the IPVS (Indian Post Visibility System), along with healthcare providers who are trusted sources of health advice, persist in their efforts to inform and promote HPV immunization. In the context of school-based vaccination programs, educators, school administrators, and the Ministry of Education also play a crucial role in conveying the advantages of HPV vaccination.

Increasing Incidence of HPV-related diseases

According to the National Cancer Registry Programme of the Indian Council of Medical Research, the estimated number of cervical cancer cases in India was over 340,000 in 2023. The incidence will further increase in the coming years because of factors such as smoking and excessive alcohol consumption, urbanization and changing lifestyles, delayed childbearing and multiple sexual partners, limited access to quality healthcare and diagnostic facilities in certain regions of India, and cultural taboos and stigmatization of certain cancers and sexually transmitted infections. This way, increasing incidences of HPV-related diseases will continue to have a positive effect on India human papillomavirus vaccine market.

Government Initiatives

Government initiatives has greatly influenced the India human papillomavirus vaccine market. The Indian government has taken proactive and comprehensive measures to tackle the public health challenge posed by human papillomavirus (HPV) infections. The primary goal of these initiatives is to increase awareness about the advantages of HPV vaccination and ensure broad vaccine coverage, with a specific focus on young girls and women. In addition to conducting awareness campaigns, the government has initiated vaccination programs and several educational initiatives to distribute information about HPV, its risks, and preventive measures.

In December 2022, the National Technical Advisory Group for Immunization (NTAGI) recommended the inclusion of the HPV vaccine in the Universal Immunization Programme (UIP). The plan involved a one-time catch-up vaccination for 9-14-year-old adolescent girls, followed by routine introduction at 9 years of age. To facilitate this vaccination drive, schools played a significant role in the implementation, adopting a grade-based approach for girls in 5th to 10th grades.

Quadrivalent Vaccines are Witnessing Rapid Growth in Demand

Increasing demand for quadrivalent vaccines has caused growth in India human papillomavirus vaccine market. The quadrivalent HPV vaccine consists of a combination of four HPV type-specific Virus-Like Particles (VLPs) derived from HPV 6, 11, 16, and 18 L1 proteins, along with an aluminum adjuvant. Clinical trials have demonstrated the vaccine’s remarkable efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 in females who have not been previously infected with the respective HPV type. It is essential to note that the vaccine does not offer protection against diseases caused by HPV types that females may already be infected with at the time of vaccination. Gardasil, a quadrivalent vaccine developed by Merck & Co. in October 2022, revealed the initial results of the clinical trial to test for two versus three doses of Gardasil vaccine in India. The clinical trials were carried out by All India Institute of Medical Sciences, New Delhi, in collaboration with several other institutes and hospitals.

High Prevalence and Government Initiatives for HPV in Eastern Region

In the Eastern region, cervical cancer is growing at a rapid rate. The district of Papumpare in the Indian state of Arunachal Pradesh has the highest incidence rate of cervical cancer (AAR-27.7) in Asia, according to the National Cancer Registry Programme. Mizoram’s Aizawl district came next, with an incidence of AAR-27.3, followed by Arunachal Pradesh’s Pasighat district, with an incidence of AAR-20.3. To reduce the prevalence of HPV, the central and state governments have started various initiatives aimed towards increasing awareness about HPV and increasing immunization drives. For example, Sikkim state made a landmark decision to be the first state in India to introduce HPV vaccine statewide. In June 2023, the Union Health Ministry administered the human papillomavirus (HPV) vaccine in the Mizoram state as a part of the universal immunization program.

Future Market Scenario (2024 – 2031F)

Increased awareness and education campaigns regarding the link between HPV and cervical cancer in India are expected to boost the adoption rate of the vaccine in the India human papillomavirus vaccine market.

The India human papillomavirus vaccine market may be greatly impacted by the government’s efforts to promote HPV vaccination, whether by including it in national immunization programs or by providing financial assistance.

Future advancements in vaccination science may lead to the development of HPV vaccinations that offer protection against new virus strains. As a result, the India human papillomavirus vaccine market may become more effective, increasing their public appeal, and maybe expanding the age range of individuals who can receive vaccinations.

Collaboration between vaccine producers, authorities, non-governmental organizations, and healthcare professionals in the India human papillomavirus vaccine market may expand the availability of HPV vaccines throughout the country, particularly in rural and impoverished areas.

Report Scope

“India Human Papillomavirus Vaccine Market Assessment, Opportunities, and Forecast, FY2017-FY2031”, is a comprehensive report by Markets and Data, providing in-depth analysis and assessment of the current scenario of the India human papillomavirus vaccine market, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts (FY 2024-2031). Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/india-human-papillomavirus-vaccine-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com